How do I set a price alert for ELUT?

To set a ELUT price alert on Stock Alarm Pro, navigate to the ELUT quote page, select "Set Alert," choose your trigger type (price target, % move, RSI level, MACD, or volume breakout), and set your delivery channel. Stock Alarm Pro supports instant push notifications, SMS, and automated phone call alerts.

Can I get phone call alerts for ELUT?

Yes. Stock Alarm Pro provides real-time automated phone call alerts for ELUT. Phone call alerts ensure you are immediately awakened or interrupted during critical volatility events, overnight earnings moves, or strict stop-loss levels when silent push notifications might be overlooked.

What types of alerts can I set for ELUT?

Stock Alarm Pro supports over 125 trigger types for ELUT: price target alerts (above/below target), intraday percentage moves, RSI overbought/oversold levels, 50-day and 200-day moving average crossovers (golden cross / death cross), relative volume (RVOL) spikes, confirmed earnings date releases, and SEC Form-4 insider transaction filings.

How quickly will I be notified about ELUT price changes?

ELUT alerts are evaluated continuously in real-time against live market telemetry. Notifications are dispatched within sub-second latency via push notifications, SMS, or phone calls as soon as your trigger condition is met across regular, pre-market, and after-hours trading sessions.

Is Stock Alarm Pro free to use for ELUT alerts?

Yes, Stock Alarm Pro offers a free tier that includes 3 active price alerts for ELUT and other stocks. Full Pro membership is $20/month or $168/year with a 7-day free trial, unlocking unlimited alerts, phone call delivery, SMS, all 125+ technical indicators, institutional screeners, and real-time market telemetry across web, iOS, and Android.

Elutia Inc(ELUT)

$0.78—

WatchlistAsk AI Chart

Elutia Inc(ELUT)

NASDAQAbout this data

$0.78—

WatchlistAsk AI Chart Studio

ELUT(ELUT)

ELUT

10/7/26

Elutia (ELUT)

Wednesday

8:51 AM

ThesisElutia: the risks are mounting — Reimbursement pressure from CMS and private payers questioning cost-effectiveness of premium biologics versus lower-cost…

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$12M	$8M	$4M
Rev. Growth	-49.6%	-39.0%	-42.7%
EPS	$1.29	$-0.63	$-0.54
EPS Growth	+169%	-149%	+14.3%
P/E	0.6×	—	—

★ Analysts see FY2026 revenue reaching $8M — -39.0% growth in a single year.

What Could Go Wrong

01Reimbursement pressure from CMS and private payers questioning cost-effectiveness of premium biologics versus lower-cost synthetic alternatives, particularly as healthcare systems focus on value-based care
02Regulatory pathway uncertainty for combination products and evolving FDA standards for biological scaffolds requiring additional clinical evidence
03Technology disruption from synthetic mesh innovations, antimicrobial coatings, or alternative infection prevention strategies that could commoditize the market
04Well-capitalized competitors including Integra LifeSciences, Medtronic, and BD offering competing biological and synthetic products with larger sales forces and established hospital relationships
05Physician adoption barriers due to learning curve with new products and loyalty to existing solutions, particularly in conservative cardiac surgery market
06Pricing pressure from group purchasing organizations and hospital value analysis committees demanding outcomes data to justify premium pricing
07Imminent liquidity crisis with current ratio of 0.44 and estimated cash runway of 6-12 months requiring dilutive equity raise or debt restructuring in 2026
08Negative tangible book value and negative equity position limiting financing options and making bankruptcy or asset sale scenarios plausible if commercial traction disappoints

FY2025 Snapshot

Revenue: $12M
Rev. Growth: -49.6%
Gross Margin: 53.7%
Op. Margin: -150%
Net Margin: 434%
Net Income: $53M
NI Growth: +199%
EPS: $1.29
1Y Return: -11.7%

ELUT Chart

My Notes

momentum/speculative - The 72% three-month return followed by -58% one-year return indicates highly speculative trading driven by clinical…
High interest rates significantly impact Elutia through multiple channels: (1) Higher cost of capital makes equity financing more dilutive…
Watch on earnings: Monthly cash balance and burn rate to assess runway and financing urgency, CanGaroo unit sales and average selling price trends indicating market penetration, Hospital formulary additions and GPO contract wins expanding addressable market.

One Sentence Summary:

The bear case: reimbursement pressure from cms and private payers questioning cost-effectiveness of premium biologics versus lower-cost synthetic alternatives.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

Stock Comparison

Compare equities side by side

52-Week Highs Breakout

Stocks breaking to new annual highs

52-Week Lows Oversold

S&P 500 oversold value screener

Trending Momentum

Relative strength momentum leaders

Earnings Calendar

Upcoming earnings dates & reports

S&P 500 Screener

Filter and sort all 500 stocks

Strategy Focus List

Continuous multi-factor scoring & catalyst forensics

Market Movers

Today's biggest gainers and losers

Metric

FY2025

FY2026E

FY2027E

P/E

0.6×

—

What Could Go Wrong

01Reimbursement pressure from CMS and private payers questioning cost-effectiveness of premium biologics versus lower-cost synthetic alternatives, particularly as healthcare systems focus on value-based care

02Regulatory pathway uncertainty for combination products and evolving FDA standards for biological scaffolds requiring additional clinical evidence

03Technology disruption from synthetic mesh innovations, antimicrobial coatings, or alternative infection prevention strategies that could commoditize the market

04Well-capitalized competitors including Integra LifeSciences, Medtronic, and BD offering competing biological and synthetic products with larger sales forces and established hospital relationships

05Physician adoption barriers due to learning curve with new products and loyalty to existing solutions, particularly in conservative cardiac surgery market

06Pricing pressure from group purchasing organizations and hospital value analysis committees demanding outcomes data to justify premium pricing

07Imminent liquidity crisis with current ratio of 0.44 and estimated cash runway of 6-12 months requiring dilutive equity raise or debt restructuring in 2026

08Negative tangible book value and negative equity position limiting financing options and making bankruptcy or asset sale scenarios plausible if commercial traction disappoints

My Notes

momentum/speculative - The 72% three-month return followed by -58% one-year return indicates highly speculative trading driven by clinical…

High interest rates significantly impact Elutia through multiple channels: (1) Higher cost of capital makes equity financing more dilutive…

Watch on earnings: Monthly cash balance and burn rate to assess runway and financing urgency, CanGaroo unit sales and average selling price trends indicating market penetration, Hospital formulary additions and GPO contract wins expanding addressable market.